Bluebird bio's experimental therapy for the genetic blood disorder beta-thalassemia major is working just as the biotech planned, using a single dose to wean two more patients off of the chronic transfusions required to treat the disease.
stereotyp72
: da sind schon wieder 9 Mio Stück short dabei
Obwohl offenbar in 2015 bereits ein Short-Squeeze war, wird nun wieder der steigende Kurs geshortet. Im Sommer ist eine klare Bodenbildung erkennbar. Normalerweise handelt man nicht über Monate gegen den Trend. Rätselhaft, warum die Bären derart hohe Risiken eingehen. Es gibt doch genug andere Handelsmöglichkeiten.
Cash Position: Cash, cash equivalents and marketable securities as of September 30, 2016 were $727.6 million, compared to $865.8 million as of December 31, 2015, a decrease of $138.2 million.
bluebird bio Announces Interim Phase 1 Dose Escalation Data for its Anti-BCMA CAR T Product Candidate in Patients with Relapsed/Refractory Multiple Myeloma
Realistisch betrachtet muss man es wohl soo sehen; “What we’re seeing here that there is a clear dose response,” says bluebird R&D chief David Davidson. “To see a median PFS of 11.8 months in this heavily pretreated patient population is very encouraging.” https://endpts.com/...CAR-T%20%20but%20fall%20short%20for%20investors
|
Thread abonnieren
